Heron Therapeutics reports Q1 EPS (4c), consensus (2c)

Reports Q1 revenue $34.71M, consensus $36.72M. “Despite typical first-quarter seasonality and unusual weather-related disruption early in the quarter, we saw a clear recovery in February and March,” said Craig Collard, Chief Executive Officer of Heron. “Our Acute Care franchise continues to perform with strong year-over-year growth, and we remain confident in our full-year framework as deferred elective procedures return and our commercial catalysts such as IGNITE 2.0, unique J-Codes, and planned sales force expansion for the Acute Care franchise continue to build through 2026.”